Patent ID: 7300644

Claim:
A method for treating a patient with cancer comprising: (A) delivering a first conjugate comprising a multispecific antibody or antibody fragment and a first anti-cancer agent, wherein said multispecific antibody or antibody fragment binds to (i) at least one marker substance selected from the group consisting of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), CD20, colon-specific antigen-p (CSAp), HLA-DR, human chorionic gonadrotropin, prostatic acid phosphatase (PAP), mammary tumor-associated glycoprotein, ovarian cystadenocarcinoma-associated antigen, ovarian tumor specific antigen, cervical cancer antigen, cytoplasmic melanoma associated antigen, melanoma cell surface antigen, breast cancer cell surface antigen, lung cancer cell surface antigen, colorectal cancer cell surface antigen, gastric cancer cell surface antigen, pancreatic cancer cell surface antigen, glioma cell surface antigen, common sarcomal cell surface antigen, gastrointestinal cancer cell surface antigen, brain tumor cell surface antigen, esophageal cancer cell surface antigen, common epithelial cancer cell surface antigen, osteosarcoma cell surface antigen, fibrosarcoma cell surface antigen, urinary bladder cancer cell surface antigen, prostatic cancer cell surface antigen, renal cancer cell surface antigen, ovarian cancer cell surface antigen, testicular cancer cell surface antigen, endometrial cancer cell surface antigen, Hodgkin's disease cell surface antigen, lymphoma cell surface antigen, leukemic cell surface antigen and trophoblastic tumor cell surface antigen, said cancer selected from the group consisting of a carcinoma, sarcoma, glioma, lymphoma, leukemia, melanoma and myeloma; and (ii) a first hapten; (B) optionally, administering a clearing agent; (C) delivering a second conjugate comprising a second hapten wherein said second hapten crosslinks to more than one multispecific antibodies or antibody fragments to increase cellular internalization, and a second anti-cancer agent, wherein said second anti-cancer agent comprises a drug-polymer conjugate; and (D) inducing said cellular internalization of said multi-specific antibody or antibody fragment.